FDA grants bioMérieux emergency authorization for one-hour Ebola Dx

BioFire Diagnostics, a subsidiary of French diagnostics outfit bioMérieux, was granted emergency authorization from the FDA for two of its Ebola tests. The company's FilmArray BioThreat-E diagnostic can detect the disease in a blood or urine sample in one hour, beating out current tests which take one to two days to deliver results. The test also forgoes the need for specialized lab processing, as it runs on BioFire lab equipment available in more than 300 U.S. hospitals, Reuters reports. Story | More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.